Kompensācijas kārtības ietvaros izrakstīto SGLT2 inhibitoru biežums salīdzinājumā ar citiem medikamentiem hroniskas sirds mazspējas gadījumā Latvijā 2024. gadā
Loading...
Date
Authors
Advisor
Journal Title
Journal ISSN
Volume Title
Publisher
Latvijas Universitāte
Language
lav
Abstract
Darba aktualitāte: Hroniska sirds mazspēja (HSM) ir globāla sabiedrības veselības problēma, kas skar miljoniem cilvēku pasaulē. HSM ārstēšanā nozīmīga loma ir medikamentozai terapijai, kas bieži ietver vairāku grupu medikamentus optimāla efekta sasniegšanai. Nātrija-glikozes ko-transportiera-2 inhibitori (SGLT2i) sākotnēji tika izmantoti tikai 2. tipa cukura diabēta ārstēšanai, taču tie ir pierādījuši ievērojamus ieguvumus sirds un asinsvadu veselībai. Ar 2023. gada septembri SGLT2 inhibitori tika iekļauti Latvijas Republikas kompensācijas sarakstā pie HSM jeb diagnozes koda I50. Darba mērķis: Novērtēt visu valsts apmaksāto SGLT-2 inhibitoru izsniegšanu Latvijā 2024. gadā pie diagnozes I50. Metodes: Izmantojot Latvijas Republikas Nacionālā veselības dienesta (NVD) datus, retrospektīvi tie tika analizēti kompensācijas kārtības ietvaros pie diagnozes I50 izsniegtās visas SGLT2 inhibitoru vienības 2024. gadā, no janvāra līdz decembrim. Rezultāti: 2024. gadā Latvijā kompensācijas ietvaros izrakstīti 1 109 631 vienību SGLT2 inhibitoru, veidojot 24,7% no visiem HSM terapijai paredzētajiem medikamentiem. To lietošana pieauga par 279% gada laikā, īpaši dominējot gada otrajā pusē. SGLT2i kļuva par otro visvairāk izrakstīto grupu pēc ARNI (1 993 576 € jeb 44,4% no kopējām izmaksām). Empagliflozīnam valsts iztērēja par 38% vairāk nekā dapagliflozīnam (attiecīgi 643 421€ un 466 210 €), lai gan empagliflozīna vienības cena bija zemāka. Secinājumi: SGLT2 inhibitoru lietojums Latvijā 2024. gadā būtiski pieauga, sasniedzot otro vietu pēc ARNI valsts kompensācijās. Empagliflozīns tika izrakstīts biežāk nekā dapagliflozīns, valsts izdevumiem par to pārsniedzot 643 tūkstošus eiro. Rezultāti atbilst starptautisko vadlīniju rekomendācijām un atspoguļo šīs terapijas nostiprināšanās pamatotību HSM ārstēšanā.
Relevance of the topic: Chronic heart failure (CHF) is a global public health issue affecting millions of people. Pharmacotherapy plays a crucial role in the management of CHF, often requiring the combination of multiple drug classes to achieve optimal outcomes. Sodium-glucose co-transporter 2 inhibitors (SGLT2i), initially developed for the treatment of type 2 diabetes mellitus, have demonstrated significant cardiovascular and renal benefits. As of September 2023, SGLT2 inhibitors have been included in the reimbursement list in the Republic of Latvia for the diagnosis code I50 – chronic heart failure. Aim of the study: To assess the dispensing frequency of all state-reimbursed SGLT2 inhibitors for chronic heart failure (ICD-10 code I50) in Latvia during the year 2024. Methods: Using data from the National Health Service of the Republic of Latvia, a retrospective analysis was conducted on all SGLT2 inhibitor units dispensed under the reimbursement system for diagnosis I50 from January to December 2024. Results: In 2024, a total of 1,109,631 SGLT2 inhibitor units were reimbursed in Latvia, accounting for 24.7% of all CHF medications. Usage increased by 279% throughout the year, with the highest growth observed in the second half of the year. SGLT2 inhibitors became the second most prescribed drug group after ARNI (1,993,576 € or 44.4% of total CHF medication costs). Empagliflozin was prescribed more frequently than dapagliflozin, and state expenses for it reached 643,421 €, which is 38% more than for dapagliflozin (466,210 €), despite a lower cost per unit. By the end of the year, the number of dispensed SGLT2i units surpassed those of both ARNI and MRA. In comparison, the average increase in usage across other CHF medication groups was only 4.5%. Conclusions: The use of SGLT2 inhibitors in Latvia increased significantly in 2024, reaching second place after ARNI in terms of state reimbursement. Empagliflozin was prescribed more frequently than dapagliflozin, with state expenditures for it exceeding 643 thousand euros. The results align with international guideline recommendations and reflect the justified consolidation of this therapy in the treatment of heart failure.
Relevance of the topic: Chronic heart failure (CHF) is a global public health issue affecting millions of people. Pharmacotherapy plays a crucial role in the management of CHF, often requiring the combination of multiple drug classes to achieve optimal outcomes. Sodium-glucose co-transporter 2 inhibitors (SGLT2i), initially developed for the treatment of type 2 diabetes mellitus, have demonstrated significant cardiovascular and renal benefits. As of September 2023, SGLT2 inhibitors have been included in the reimbursement list in the Republic of Latvia for the diagnosis code I50 – chronic heart failure. Aim of the study: To assess the dispensing frequency of all state-reimbursed SGLT2 inhibitors for chronic heart failure (ICD-10 code I50) in Latvia during the year 2024. Methods: Using data from the National Health Service of the Republic of Latvia, a retrospective analysis was conducted on all SGLT2 inhibitor units dispensed under the reimbursement system for diagnosis I50 from January to December 2024. Results: In 2024, a total of 1,109,631 SGLT2 inhibitor units were reimbursed in Latvia, accounting for 24.7% of all CHF medications. Usage increased by 279% throughout the year, with the highest growth observed in the second half of the year. SGLT2 inhibitors became the second most prescribed drug group after ARNI (1,993,576 € or 44.4% of total CHF medication costs). Empagliflozin was prescribed more frequently than dapagliflozin, and state expenses for it reached 643,421 €, which is 38% more than for dapagliflozin (466,210 €), despite a lower cost per unit. By the end of the year, the number of dispensed SGLT2i units surpassed those of both ARNI and MRA. In comparison, the average increase in usage across other CHF medication groups was only 4.5%. Conclusions: The use of SGLT2 inhibitors in Latvia increased significantly in 2024, reaching second place after ARNI in terms of state reimbursement. Empagliflozin was prescribed more frequently than dapagliflozin, with state expenditures for it exceeding 643 thousand euros. The results align with international guideline recommendations and reflect the justified consolidation of this therapy in the treatment of heart failure.